SAMN03290938
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ANGIOGENESIS+0.200
- INTERFERON_ALPHA_RESPONSE+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- PANCREAS_BETA_CELLS+0.200
- ANDROGEN_RESPONSE+0.100
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.400
- MITOTIC_SPINDLE-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- APICAL_SURFACE-0.300
- DNA_REPAIR-0.300
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- TGF_BETA_SIGNALING-0.300
- APICAL_JUNCTION-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 38ac1da2-32a1-4530-a553-e5adff884b4f | — | — | 0.852 |
| 2 | SRR8518255 | — | D | 0.815 |
| 3 | ff12dc45-d7ab-45ae-a049-2d20e3c546b6 | — | — | 0.782 |
| 4 | SRR25617861 | — | A | 0.761 |
| 5 | SRR8518324 | — | D | 0.759 |
| 6 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.759 |
| 7 | TCGA-55-6987-01A-11R-1949-07 | — | cohortMD2 | 0.756 |
| 8 | SRR8518300 | — | A | 0.752 |
| 9 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.742 |
| 10 | SRR2932829 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |